<DOC>
	<DOC>NCT02074982</DOC>
	<brief_summary>This study will assess efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis</brief_summary>
	<brief_title>Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>patients with moderate to severe plaque type psoriasis for at least 6 months before randomization patients eligible for systemic therapy with inadequately controlled psoriasis forms of sporiasis other than plaque type psoriasis previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)17A or IL17RA Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>chronic plaque type psoriasis, secukinumab, ustekinumab, inflammatory skin disease, scaling</keyword>
</DOC>